Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb 20:2020:4631297.
doi: 10.1155/2020/4631297. eCollection 2020.

Pneumocystis jirovecii Pneumonia in Patients with Nephrotic Syndrome: Application of Lymphocyte Subset Analysis in Predicting Clinical Outcomes

Affiliations

Pneumocystis jirovecii Pneumonia in Patients with Nephrotic Syndrome: Application of Lymphocyte Subset Analysis in Predicting Clinical Outcomes

Yang Liu et al. Can J Infect Dis Med Microbiol. .

Abstract

Purpose: With immunosuppressants being widely used, Pneumocystis jirovecii pneumonia (PCP) has been increasing and could be life-threatening among HIV-negative patients. This study aimed at identifying prognostic factors of PCP in patients with nephrotic syndrome.

Methods: We retrospectively investigated patients with nephrotic syndrome who were diagnosed with PCP. The diagnosis of PCP was based on clinical manifestations, radiological findings, and microbiological confirmatory tests. Predictors of outcome were determined with multivariate logistic regression analysis.

Results: A total of 57 patients were included in this study. The PCP mortality was 33.3%, which increased to 48.6% if ICU admission was required and to 60% when mechanical ventilation was needed. The T lymphocyte count and CD4/CD8 ratio independently predicted the outcome of PCP, so did the CD4+ T lymphocyte count (OR, 0.981; 95% CI, 0.967-0.996; p=0.001). The cut-off value of 71 cells/μl for the CD4+ T lymphocyte count was determined to identify patients with poor prognosis. No association was found between PCP mortality and the type of immunosuppressant used.

Conclusions: PCP is a fatal complication among nephrotic syndrome patients receiving immunosuppressive therapy. The CD4+ T lymphocyte count is suggested as an independent predictor of prognosis, which can be used clinically to identify patients with high risk of unfavorable outcomes.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Predictors for PCP mortality and the influence on clinical course; (a–c) CD4+ T lymphocyte counts, T lymphocyte counts, and CD4/CD8 ratios in survivors and nonsurvivors. Error bars, mean ± SEM. (d) Mortality in patients with CD4+ T lymphocyte counts <71/μl and ≥71/μl. The dashed line indicates overall mortality of all patients (33.3%). (e) Proportion of mechanical ventilation in patients with CD4+ T lymphocyte counts <71/μl and ≥71/μl. Percentages (85.7% vs. 33.3%) shown in the graph represent the proportions of mechanical ventilation including both noninvasive and invasive ventilation. (f) Survival analysis of in-ICU patients stratified for CD4+ T lymphocyte counts <71/μl and ≥71/μl. p value, log-rank test. Non-MV: mechanical ventilation not applied, NIMV: noninvasive mechanical ventilation, and IMV: invasive mechanical ventilation.

Similar articles

Cited by

References

    1. Maini R., Henderson K. L., Sheridan E. A., et al. Increasing Pneumocystis pneumonia, England, UK, 2000–2010. Emerging Infectious Diseases. 2013;19(3):386–392. doi: 10.3201/eid1903.121151. - DOI - PMC - PubMed
    1. Pagano L., Caira M., Fianchi L. Pulmonary fungal infection with yeasts and pneumocystisin patients with hematological malignancy. Annals of Medicine. 2005;37(4):259–269. doi: 10.1080/07853890510037374. - DOI - PubMed
    1. Mikaelsson L., Jacobsson G., Andersson R. Pneumocystis pneumonia-a retrospective study 1991–2001 in Gothenburg, Sweden. Journal of Infection. 2006;53(4):260–265. doi: 10.1016/j.jinf.2005.06.014. - DOI - PubMed
    1. Catherinot E., Lanternier F., Bougnoux M.-E., Lecuit M., Couderc L.-J., Lortholary O. Pneumocystis jirovecii pneumonia. Infectious Disease Clinics of North America. 2010;24(1):107–138. doi: 10.1016/j.idc.2009.10.010. - DOI - PubMed
    1. Monnet X., Vidal-Petiot E., Osman D., et al. Critical care management and outcome of severe Pneumocystis pneumonia in patients with and without HIV infection. Critical Care. 2008;12(1):p. R28. doi: 10.1186/cc6806. - DOI - PMC - PubMed